Cyclacel Pharmaceuticals Sees 36.25% Stock Surge Amid Strategic Acquisitions

Introduction

Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) is a clinical-stage biopharmaceutical company focused on developing oral therapies that target cell cycle control for oncology and hematology indications. As of July 23, 2025, CYCC shares were priced at $14.66, reflecting a price change of 36.25% on the day, with a trading volume of 577,620 shares on the NASDAQ Capital Market.

Corporate Structure

Founded in 1996 by Sir David Lane, Merlin Ventures, and Cancer Research Campaign Technology in collaboration with the University of Dundee and the University of Glasgow, Cyclacel is headquartered in Dundee, Scotland, with a U.S. office in Short Hills, New Jersey. The company employs between 11 and 50 staff, which includes scientists, clinical development specialists, and corporate personnel. Cyclacel’s leadership team possesses expertise in cell cycle biology, transcriptional regulation, epigenetics, and mitosis biology.

Biopharmaceuticals by little plant

Recent Developments and News

On May 6, 2025, Cyclacel entered into a share exchange agreement with FITTERS Diversified Berhad to acquire its subsidiary, Fitters Sdn. Bhd., making it a wholly-owned subsidiary. Under the agreement, Cyclacel will issue common stock representing 19.99% of its outstanding shares as of the closing date, with existing shareholders retaining approximately 80.01% of the combined company. Following the transaction, Cyclacel plans to rename itself Bio Green Med Solution, Inc. and continue trading on NASDAQ under a new ticker symbol.
On June 18, 2025, the company’s Majority Consenting Stockholder approved a Securities Purchase Agreement to sell 3,000,000 shares of Series F Convertible Preferred Stock at $1.00 per share, along with 29,430,000 warrants. This financing closed on June 20, 2025, generating gross proceeds of $3.0 million for general corporate purposes.
On July 7, 2025, Cyclacel filed a DEF 14C definitive information statement detailing the Series F issuance, including a conversion cap of 4.99% of outstanding common stock without further stockholder approval. On July 16, 2025, the company submitted a Form 8-K reporting items 7.01 and 9.01 related to current developments, as well as a Rule 425 communication regarding the pending business combination.

Financial and Strategic Analysis

Cyclacel’s sale of Series F Preferred Stock on June 20, 2025, raised $3.0 million to support ongoing operations and clinical programs. The linked issuance of warrants may result in equity dilution but reinforces the company’s efforts to maintain liquidity.
The share exchange with FITTERS introduces a non-pharmaceutical subsidiary into Cyclacel’s corporate structure, broadening its asset base beyond oncology. Existing Cyclacel shareholders will hold an 80.01% stake in the combined entity.

Market Position and Industry Context

Cyclacel operates in the competitive oncology sector, differentiating itself through the development of oral inhibitors targeting key cell cycle components. Its lead programs include:

• Fadraciclib (CYC065), a CDK2/9 inhibitor currently in Phase 1/2 trials for advanced solid tumors and lymphoma.
• Plogosertib (CYC140), a PLK1 inhibitor under evaluation for both solid tumors and hematological malignancies.

The oral administration of these therapies offers patient convenience compared to intravenous options. Historical programs include sapacitabine (CYC682) and seliciclib (CYC202). Notably, sapacitabine’s Phase 3 trial in elderly AML patients did not meet its primary endpoint. Cyclacel’s late-stage competitors include larger firms developing CDK and PLK inhibitors, necessitating strategic partnerships and capital raising efforts to advance its pipeline.

tl;dr

Cyclacel’s stock increased by 36.25% on July 23, 2025, trading at $14.66. On May 6, 2025, the company agreed to acquire Fitters Sdn. Bhd. and plans to issue 19.99% of its shares and a corporate name change. On June 20, 2025, Cyclacel secured $3 million through Series F Convertible Preferred Stock and warrants. Regulatory filings on July 7 and July 16, 2025, provided details on these transactions. These financing and business combination efforts aim to support Cyclacel’s oral oncology pipeline while diversifying its asset base.